Insider · CIK 0001394645
Samuel J Reich
Files at SABS (SAB Biotherapeutics, Inc.). First filing -, latest -.
Samuel J Reich files SEC Form 4 as CEO, chair and director at SABS (SAB Biotherapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Samuel J Reich has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | SABS SAB Biotherapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +4,800,000 | $0.00 | $0 | 4,800,000 | Feb 5, 2026 |
| Aug 26, 2025 | SABS SAB Biotherapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +4,800,000 | $0.00 | $0 | 4,800,000 | Aug 28, 2025 |
Questions about Samuel J Reich
Answered from the filings on this page, as of the latest one.
Is Samuel J Reich buying or selling?
Samuel J Reich has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Samuel J Reich's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Samuel J Reich has 0.
Where does Samuel J Reich file Form 4?
Samuel J Reich has filed Form 4 at SABS (SAB Biotherapeutics, Inc.) as CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.